2 years ago

Medherant Secures £3 Million to Advance Menopausal Testosterone Patch

  • Medherant, a UK-based biotechnology company developing a testosterone patch for women with menopausal symptoms, has raised £3 million in funding from Mercia Asset Management

  • The company plans to use the funds to accelerate its growth and research efforts, aiming to begin clinical trials later this year and gain regulatory approval in the UK and internationally.

      • ProblemHealthcare

      "Millions of women around the world experience debilitating menopausal symptoms, but current treatment options are often ineffective or inconvenient."

      Solution

      "Medherant has developed a convenient and effective testosterone patch that delivers the right amount of hormones twice a week, potentially offering a better solution for women dealing with menopause."

      Covered on